2013-10-07 09:01 PM
INGELHEIM, Germany--(BUSINESS WIRE)--Oct 7, 2013--For media outside of the US, the UK & Canada only
Anticoagulants are an indispensable treatment to prevent dangerous blood clots that can cause devastating ischaemic strokes in patients with atrial fibrillation or life-threatening pulmonary embolism in patients with venous thromboembolism. 1,2 An increased risk of bleeding is a known possible complication of all anticoagulant therapies. 3 This research shows that applying existing management strategies in case of a major bleed with Pradaxa R compared to a major bleed with warfarin resulted in better outcomes even without the availability of a specific antidote. 4
A post-hoc analysis of five Phase III trials compared the management and outcomes of a major bleeding event in patients taking Pradaxa R (dabigatran etexilate) with major bleeding events in patients taking warfarin. The results are now published online in Circulation. The analysis showed that the 30-day mortality (death within one month) related to a major bleeding event was significantly lower with Pradaxa R than with warfarin in atrial fibrillation patients requiring long-term treatment in the RE-LY R trial. In addition, Pradaxa R treated patients could leave the Intensive Care Unit faster than warfarin treated patients. 4
When major bleeding did occur in the trials analysed, the patients were managed using standard strategies and treatment options currently available in the clinical setting, both for Pradaxa R and warfarin. 4 This better outcome in case of a major bleed, even in the absence of a specific antidote, provides crucial support for the positive benefit-risk profile of Pradaxa R.
"We found that atrial fibrillation patients, who had a major bleed during therapy, actually had better outcomes if they took dabigatran than if they took warfarin," said Prof. Sam Schulman, Division of Hematology and Thromboembolism, McMaster University, Hamilton, Canada. "It is reassuring to see that existing standard strategies, such as stopping the drug and replacing blood, work just as well with dabigatran treatment as they do with warfarin treatment ?V if not even better."
The analysis also found that patients who had a major bleeding event during Pradaxa R treatment were usually at higher baseline risk compared to patients with major bleeding events on warfarin ?V Pradaxa R patients were older, had worse renal function and more often used concomitant treatment with aspirin or non-steroid anti-inflammatory agents. 4
The pooled post-hoc analysis featured data from five large long-term Phase III trials including the pivotal RE-LY R trial comparing Pradaxa R with warfarin for stroke prevention in non-valvular atrial fibrillation and trials in acute treatment / secondary prevention of venous thromboembolism (VTE). The trials had durations of six to 36 months and included 27,419 patients. Key results are: 4
Lower 30-day mortality in case of a first major bleed in the combined Pradaxa R treatment group compared to the warfarin group in atrial fibrillation patients (odds ratio 0.56, p=0.009)
When outcomes for all indications were combined and adjusted, the data showed a strong trend to lower mortality for Pradaxa R compared to warfarin (odds ratio 0.66, p=0.051)
One day shorter stay in the intensive care unit required for Pradaxa R patients (mean 1.6 nights) compared with warfarin patients (mean 2.7 nights; p=0.01)
Most major bleeds were managed mainly with supportive care using standard clinical measures. The most common measures used were blood transfusions and plasma transfusions.
"These findings provide important and reassuring insights for both physicians and patients", commented Professor Klaus Dugi, Corporate Senior Vice President Medicine, Boehringer Ingelheim. "They demonstrate that even in the absence of a specific antidote, when existing standard strategies are used, patients can expect a better outcome with Pradaxa R than with warfarin should a major bleed occur."
The favourable benefit-risk profile of Pradaxa R is supported by safety assessments from regulatory authorities including the European Medicines Agency and the U.S. Food and Drug Administration (FDA). 5,6 The most recent FDA update reports the results of a Mini-Sentinel assessment that indicated bleeding rates associated with new use of Pradaxa R are not higher than those associated with new use of warfarin. Specifically, for intracranial haemorrhage and gastrointestinal haemorrhage, the combined incidence rate (per 100,000 days at risk) was 1.8 to 2.6 times higher for new users of warfarin than for new users of Pradaxa R. 6
Pradaxa R is already widely approved for stroke prevention in atrial fibrillation and for primary prevention of VTE following total hip replacement or total knee replacement surgery. 7 The extensive in-market experience of over 2 million patient-years in all licensed indications puts Pradaxa R first among the novel oral anticoagulants. 8
Please click on the link for 'Notes to Editors' and 'References': http://www.boehringer-ingelheim.com/news/news_releases/press_releases/2013/07_october_2013_dabigatranetexilate.html
CONTACT: Boehringer Ingelheim GmbH
Media + PR
Phone: +49 6132 - 77 8271
Fax: +49 6132 - 77 6601
KEYWORD: EUROPE GERMANY
INDUSTRY KEYWORD: SURGERY HEALTH BIOTECHNOLOGY CARDIOLOGY CLINICAL TRIALS PHARMACEUTICAL RESEARCH SCIENCE
SOURCE: Boehringer Ingleheim
Copyright Business Wire 2013
PUB: 10/07/2013 08:32 AM/DISC: 10/07/2013 08:32 AM